[go: up one dir, main page]

WO1998008535A3 - Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 - Google Patents

Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 Download PDF

Info

Publication number
WO1998008535A3
WO1998008535A3 PCT/US1997/015016 US9715016W WO9808535A3 WO 1998008535 A3 WO1998008535 A3 WO 1998008535A3 US 9715016 W US9715016 W US 9715016W WO 9808535 A3 WO9808535 A3 WO 9808535A3
Authority
WO
WIPO (PCT)
Prior art keywords
lectin
treating
causing selective
tumor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/015016
Other languages
English (en)
Other versions
WO1998008535A2 (fr
Inventor
Linda G Baum
Nancy L Perillo
Jeffrey J Seilhamer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD, Incyte Pharmaceuticals Inc filed Critical University of California Berkeley
Priority to AU40913/97A priority Critical patent/AU4091397A/en
Publication of WO1998008535A2 publication Critical patent/WO1998008535A2/fr
Publication of WO1998008535A3 publication Critical patent/WO1998008535A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à des procédés de traitement de maladies néoplasiques caractérisées par la prolifération de lymphocytes. Lesdits procédés consistent à administrer des compositions pharmaceutiques contenant une lectine soluble possédant un poids moléculaire d'environ 14 kilodaltons. L'invention se rapporte en outre à des procédés de traitement de tumeurs productrices de lectine qui consistent à administrer une quantité efficace d'un anticorps qui se lie de manière spécifique à la lectine, aux antagonistes de la lectine, à des saccharides inhibiteurs ou à des inhibiteurs de glycosylation dans le but de prévenir l'apoptose induite par les lectines des lymphocytes T infiltrés dans la tumeur.
PCT/US1997/015016 1996-08-26 1997-08-26 Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 Ceased WO1998008535A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40913/97A AU4091397A (en) 1996-08-26 1997-08-26 Method of causing selective immunosuppression using hl-60-related lectins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70480296A 1996-08-26 1996-08-26
US08/704,802 1996-08-26

Publications (2)

Publication Number Publication Date
WO1998008535A2 WO1998008535A2 (fr) 1998-03-05
WO1998008535A3 true WO1998008535A3 (fr) 1998-05-28

Family

ID=24830917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015016 Ceased WO1998008535A2 (fr) 1996-08-26 1997-08-26 Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60

Country Status (2)

Country Link
AU (1) AU4091397A (fr)
WO (1) WO1998008535A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890531B1 (en) 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
TW200617393A (en) * 2004-11-22 2006-06-01 Univ Nat Cheng Kung Method for testing lectin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337799A2 (fr) * 1988-04-14 1989-10-18 Incyte Pharmaceuticals, Inc. Lectines 14-bêta-gal de mammifères
WO1992019239A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
WO1994011497A1 (fr) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337799A2 (fr) * 1988-04-14 1989-10-18 Incyte Pharmaceuticals, Inc. Lectines 14-bêta-gal de mammifères
WO1992019239A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
WO1994011497A1 (fr) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60

Also Published As

Publication number Publication date
AU4091397A (en) 1998-03-19
WO1998008535A2 (fr) 1998-03-05

Similar Documents

Publication Publication Date Title
BG104245A (en) Plasma protein-containing pharmaceutical compositions
CA2271857A1 (fr) Methode pour traiter les symptomes du diabete
CA2162600A1 (fr) Compositions renfermant des proteines associees au complement recepteur et des carbohydrates; methodes de preparation et d'utilisation de ces compositions
WO2002002638A3 (fr) Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble
CA2146973A1 (fr) Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques
DZ2172A1 (fr) Dérivés de triazole utiles on thérapeutique, procédé pour leur préparation et compositions les contenant.
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
EP1273304A3 (fr) Utilisation de l'interleukine-15
OA09374A (fr) "Nouveaux 1, 2, 3, 4, 5, 6-hexahydroazépino [4,5-b] indoles et 1, 2, 3, 4-tétrahydro B carbolines, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent".
CA2278422A1 (fr) D-methadone, analgesique non opioide
EP0999219A3 (fr) Peptides se liant á l'heparine
IT8904847A0 (it) Veicolo cingolato, in particolare per la preparazione di piste da sci.
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
WO1998008535A3 (fr) Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60
ITMI912745A0 (it) Derivati 5h-benzodiazepinici, composizioni farmaceutiche che li contengono e procedimento per la loro preparazione.
FR2652487B1 (fr) Dispositif de protection contre l'usure, pour chaussures.
CA2066031A1 (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
IT8719700A0 (it) 2-tiometil-sostituite-piridine, metodo per la loro preparazione e composizioni farmaceutiche che le contengono.
IT8125431A0 (it) Dispositivo per la preparazione dimateriale granuloso, in particolare di terra da fonderie.
GB2244998B (en) Extracellular expolymer,process for its preparation and pharmaceutical compositions containing the said exopolymer
FR2698799B1 (fr) Machine pour aplatir les grains de céréales, notamment.
IT8119758A0 (it) Derivati 2'-deossi-3',5'-di-o-alchilcarbonil-5-fluorouri dinici processo per la loro preparazione e agenti antitumorali che contengono i detti derivati.
IT1210859B (it) Composto chemioterapico, procedimento per la sua preparazione e relative composizioni farmaceutiche.
KUROKI Performance of Meat Oligopolistic Business Group Focused on full-cost principle
IT8622783A0 (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511850

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA